Citation Impact
Citing Papers
Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense
2016 Standout
Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections.
2007
Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
2013
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics
2021 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2007 Standout
Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study
2006
Ocular toxicity of systemic asthma and allergy treatments
2006
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
2010 Standout
Mitogen-activated protein kinases in innate immunity
2013
Cystic fibrosis
2016 Standout
Premature discontinuation of patients: a potential bias in COPD clinical trials
2007
COPD Guidelines: A Review of the 2018 GOLD Report
2018 Standout
Diagnosis, management, and prognosis of preschool wheeze
2014
Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease
2008
Integrated care prevents hospitalisations for exacerbations in COPD patients
2006 Standout
The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease
2004 Standout
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics
2020 Standout
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
2005 Standout
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
2014 Standout
TFOS DEWS II Diagnostic Methodology report
2017 Standout
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial
2014
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
2009 Standout
What have we learned from large drug treatment trials in COPD?
2007
Aspergillus bronchitis without significant immunocompromise
2012
COPD exacerbations: defining their cause and prevention
2007
Macrolide effects on the prevention of COPD exacerbations
2012
Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections
2006 Standout
Lung function decline and outcomes in an elderly population
2006
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
2016
Asthma
2017 Standout
Impact of preventing exacerbations on deterioration of health status in COPD
2004 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Tuberculosis and lung damage: from epidemiology to pathophysiology
2018 StandoutNobel
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
2007
Does pulmonary rehabilitation give additional benefit over tiotropium therapy in primary care management of chronic obstructive pulmonary disease? Randomized controlled clinical trial in Hong Kong Chinese
2005
Development and first validation of the COPD Assessment Test
2009 Standout
Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group
2013 Standout
Interpretative strategies for lung function tests
2005 Standout
Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited
2008
Pulmonary-intestinal cross-talk in mucosal inflammatory disease
2011
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
2014
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Azithromycin for the Prevention of COPD Exacerbations: The Good, Bad, and Ugly
2015
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
2014 Standout
Gut microbiota and Covid-19- possible link and implications
2020 Standout
Global strategy for asthma management and prevention: GINA executive summary
2007 Standout
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis
2004 Standout
Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD
2012
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
2012 Standout
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
2011
Prediction and treatment of asthma in preschool children at risk: study design and baseline data of a prospective cohort study in general practice (ARCADE)
2009
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
2007 Standout
The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease
2004 Standout
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease
2005
The natural history of community-acquired pneumonia in COPD patients: A population database analysis
2012
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
2017 Standout
Long-Term Inhaled Corticosteroids in Preschool Children at High Risk for Asthma
2006
Impact of Exacerbations on Emphysema Progression in Chronic Obstructive Pulmonary Disease
2011
Global burden of COPD: risk factors, prevalence, and future trends
2007 Standout
Women manifest more severe COPD symptoms across the life course
2018
Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid Diseases
2005 Standout
COPD exacerbations: definitions and classifications
2003
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
2008 Standout
Differences in COPD Exacerbation Risk Between Women and Men
2019
A Pooled Analysis of FEV 1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo
2007
Minimal Clinically Important Differences in Pharmacological Trials
2014
Women and Lung Disease. Sex Differences and Global Health Disparities
2015
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease
2015 StandoutNobel
Pulmonary rehabilitation for chronic obstructive pulmonary disease
2015 Standout
Lung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/Tuberculosis
2019 StandoutNobel
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program
2017
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
2012
Montelukast, Compared With Fluticasone, for Control of Asthma Among 6- to 14-Year-Old Patients With Mild Asthma: The MOSAIC Study
2005
A Common NLRC4 Gene Variant Associates With Inflammation and Pulmonary Function in Human Immunodeficiency Virus and Tuberculosis
2019 StandoutNobel
British Guideline on the Management of Asthma
2008
Cigarette smoke and CFTR: implications in the pathogenesis of COPD
2013
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
2014
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003
2003 Standout
Declines in Lung Function After Antiretroviral Therapy Initiation in Adults With Human Immunodeficiency Virus and Tuberculosis: A Potential Manifestation of Respiratory Immune Reconstitution Inflammatory Syndrome
2019 StandoutNobel
Exercise prescription for hospitalized people with chronic obstructive pulmonary disease and comorbidities: a synthesis of systematic reviews
2012
Physical Activity and Public Health in Older Adults
2007 Standout
Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease – 2007 Update
2007
The non-antibiotic macrolide EM900 inhibits rhinovirus infection and cytokine production in human airway epithelial cells
2015 StandoutNobel
Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis
2015
Works of Lisa Willits being referenced
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
2009
Adherence to inhaled therapy, mortality and hospital admission in COPD
2009
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
2009
Prevalence and Progression of Osteoporosis in Patients With COPD
2009
Withdrawal From Treatment as an Outcome in the ISOLDE Study of COPD
2003
An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease
2011
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations
2003
Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease
2010
Reported Pneumonia in Patients With COPD
2010
Cardiovascular events in patients with COPD: TORCH Study results
2010
A Comparison of Fluticasone Propionate, 100??g Twice Daily, Administered Via a CFC and Non-CFC Propellant, HFA 134a, in Adult Patients with Asthma
2001
Twelve-Month Safety and Efficacy of Inhaled Fluticasone Propionate in Children Aged 1 to 3 Years With Recurrent Wheezing
2004